AUTHOR=Liu Hui , Zhang Kaige , Liu Peng , Xu Xuan , Zhou Yuyang , Gan Lihong , Yao Ling , Li Bin , Chen Tingtao , Fang Nian 

TITLE=Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.940500

DOI=10.3389/fimmu.2022.940500

ISSN=1664-3224

ABSTRACT=<sec><title>Background</title><p>Postoperative symptoms, bowel dysfunction and recurrence are common problems after resection of colorectal polyps. We aimed to evaluate the efficacy of <italic>Bifidobacterium</italic> in the postoperative patients.</p></sec><sec><title>Methods</title><p>In this single-center, randomized, double-blind, placebo-controlled trial, adults (≥ 18 years) undergoing endoscopic resection of colorectal polyps were treated with probiotics (<italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> MH-02, 2 × 10<sup>9</sup> colony-forming units per packet) or placebo once daily for 7 days. The primary clinical endpoint was a reduction in the mean total postoperative symptoms score within 7 days postoperatively. Secondary clinical endpoints were the single symptom scores, time to recovery of bowel function, and changes in the intestinal microbiota. This study is registered with the number ChiCTR2100046687.</p></sec><sec><title>Results</title><p>A total of 100 individuals were included (48 in probiotic group and 52 in placebo group). No difference was seen in the mean scores between the two groups (0.29 vs. 0.43, P = 0.246). Colorectal polyps size (P = 0.008) and preoperative symptoms (P = 0.032) were influential factors for the primary endpoint. Besides, MH-02 alleviated difficult defecation (P = 0.045), and reduced the time to recovery of bowel function (P = 0.032). High-throughput analysis showed that MH-02 can help restore the diversity of intestinal microbiota, and increased the relative abundance of <italic>Bifidobacterium</italic>, <italic>Roseburia</italic>, <italic>Gemmiger</italic>, <italic>Blautia</italic> and <italic>Ruminococcus</italic>, while reduced the relative abundance of <italic>Clostridium</italic> at genus level (P &lt; 0.05).</p></sec><sec><title>Conclusion</title><p>In this prospective trial, MH-02 showed efficacy in patients with resection of colorectal polyps, particularly in the recovery of bowel function, and the changes in the intestinal microbiota may provide evidence for further exploration of the therapeutic mechanisms.</p></sec>